Plus Therapeutics Inc (PSTV)

$0.73 +0.05 (7.14%)
Market Cap 72.58M
Revenue (ttm) 5.82M
Net Income (ttm) -12.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1.29
Profit Margin -223.02%
Debt to Equity Ratio 0.00
Volume 22,456,000
Avg Vol 23,136,965
Day's Range N/A - N/A
Shares Out 99.27M
Stochastic %K 71%
Beta 0.81
Analysts Strong Sell
Price Target $7.88

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 255 7194
Fax: 210 974 6901
Address:
2710 Reed Road, Suite 160, Houston, United States
TWITLIEDETECTOR
TWITLIEDETECTOR Oct. 5 at 2:22 AM
$PSTV stop with the moon shit. It could not even break first level resistance last week. It needs a pr or volume
1 · Reply
investak
investak Oct. 5 at 12:06 AM
$PSTV Would you let it reverse split your shares after vesting if you are a mgmt? I don't think so.... 🤔
0 · Reply
DIDI_MAGIC
DIDI_MAGIC Oct. 4 at 11:57 PM
$PSTV @Joe747 After long waiting, it finally gonna happen! 🤣🤣🤣
1 · Reply
FreeManTrading
FreeManTrading Oct. 4 at 6:24 PM
$PSTV We have concluded our scenario. Good Luck folks! 📈💰🚀
1 · Reply
JediMasterTrader
JediMasterTrader Oct. 4 at 4:15 PM
$PSTV
0 · Reply
dang1976
dang1976 Oct. 4 at 3:57 PM
$PSTV, let’s get her to $ range next week!
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 2:04 PM
Inside Cancer Innovation Radiopharmaceuticals RADX What’s Next - YouTube $PSTV $CLRB $ATNM https://www.youtube.com/watch?v=df1JoFcU7gA
0 · Reply
Hoekie12
Hoekie12 Oct. 4 at 1:32 PM
$PSTV The director gets largd calloptions. But he can only exercise them In a four year period. About 100 K in a month. This has been done because PSTV knows that business will be great. Money flowing in. Share price to rise. So I am not worried about that 👍
3 · Reply
Keywest20
Keywest20 Oct. 4 at 12:55 PM
$PSTV
0 · Reply
Keywest20
Keywest20 Oct. 4 at 12:54 PM
$PSTV Love this
0 · Reply
Latest News on PSTV
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 25, 2025, 7:30 AM EDT - 9 days ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 22, 2025, 7:30 AM EDT - 12 days ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 18, 2025, 7:30 AM EDT - 16 days ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:15 PM EDT - 4 weeks ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 26, 2025, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 18, 2025, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 15, 2025, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 4:15 PM EDT - 7 weeks ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Aug 14, 2025, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 31, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 23, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 15, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 10, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jul 8, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 26, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 4:15 PM EDT - 3 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 25, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Jun 24, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 30, 2025, 4:15 PM EDT - 4 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 23, 2025, 4:15 PM EDT - 4 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 14, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 7:00 AM EDT - 5 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 23, 2025, 8:00 AM EDT - 5 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Apr 15, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:42 PM EDT - 6 months ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 20, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 19, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 11, 2025, 11:00 AM EDT - 7 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 10, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 7, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 6, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces New Employment Inducement Grants

Mar 5, 2025, 4:01 PM EST - 7 months ago

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Mar 4, 2025, 2:06 PM EST - 7 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Feb 26, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Feb 24, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Feb 20, 2025, 7:30 AM EST - 8 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Feb 18, 2025, 7:30 AM EST - 8 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 17, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Dec 3, 2024, 7:30 AM EST - 10 months ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Nov 25, 2024, 7:30 AM EST - 11 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Nov 22, 2024, 7:30 AM EST - 11 months ago

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Nov 21, 2024, 7:30 AM EST - 11 months ago

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

Nov 16, 2024, 2:45 PM EST - 11 months ago

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 4:15 PM EST - 11 months ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Nov 6, 2024, 7:30 AM EST - 11 months ago

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Nov 5, 2024, 7:30 AM EST - 11 months ago

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

TWITLIEDETECTOR
TWITLIEDETECTOR Oct. 5 at 2:22 AM
$PSTV stop with the moon shit. It could not even break first level resistance last week. It needs a pr or volume
1 · Reply
investak
investak Oct. 5 at 12:06 AM
$PSTV Would you let it reverse split your shares after vesting if you are a mgmt? I don't think so.... 🤔
0 · Reply
DIDI_MAGIC
DIDI_MAGIC Oct. 4 at 11:57 PM
$PSTV @Joe747 After long waiting, it finally gonna happen! 🤣🤣🤣
1 · Reply
FreeManTrading
FreeManTrading Oct. 4 at 6:24 PM
$PSTV We have concluded our scenario. Good Luck folks! 📈💰🚀
1 · Reply
JediMasterTrader
JediMasterTrader Oct. 4 at 4:15 PM
$PSTV
0 · Reply
dang1976
dang1976 Oct. 4 at 3:57 PM
$PSTV, let’s get her to $ range next week!
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 2:04 PM
Inside Cancer Innovation Radiopharmaceuticals RADX What’s Next - YouTube $PSTV $CLRB $ATNM https://www.youtube.com/watch?v=df1JoFcU7gA
0 · Reply
Hoekie12
Hoekie12 Oct. 4 at 1:32 PM
$PSTV The director gets largd calloptions. But he can only exercise them In a four year period. About 100 K in a month. This has been done because PSTV knows that business will be great. Money flowing in. Share price to rise. So I am not worried about that 👍
3 · Reply
Keywest20
Keywest20 Oct. 4 at 12:55 PM
$PSTV
0 · Reply
Keywest20
Keywest20 Oct. 4 at 12:54 PM
$PSTV Love this
0 · Reply
Keywest20
Keywest20 Oct. 4 at 12:05 PM
$PSTV that post was from August
0 · Reply
Stocky95
Stocky95 Oct. 4 at 11:27 AM
$PSTV They are getting re imbursed for cn side. Bright days ahead
1 · Reply
prakritim
prakritim Oct. 4 at 4:39 AM
$PSTV No scam they said lmao
0 · Reply
jplumberg
jplumberg Oct. 4 at 4:07 AM
$PSTV https://www.reddit.com/r/pennystocks/comments/1n2p3u9/pstv_why_just_10_percent_of_cnsides_market_by_end/
3 · Reply
HeilHiden
HeilHiden Oct. 4 at 1:00 AM
$PSTV support is close by and nearest resistance is just a stop before open skies. I’ll be watching Monday. See yall then have a blessed weekend
3 · Reply
Vulnerable
Vulnerable Oct. 4 at 12:27 AM
$PSTV Mo, where we at with updates? What was the last count? 9 updates pending. Have 3 or 4 come out? Seems like we are due for the negative updates. @Love_To_Learn blocked me, appreciate someone tagging him for an update on PSTV updates. thanks.
0 · Reply
greenday88
greenday88 Oct. 4 at 12:16 AM
$PSTV whats the deadline for compliance to reach $1. is this the first time? coz normally they give you "one more chance" to get your books in order if you can prove the company is sound
2 · Reply
Keywest20
Keywest20 Oct. 4 at 12:14 AM
$BURU $ICU $IMG $PSTV $QCLS Really that’s all you got!!!
0 · Reply
Nopunchclock
Nopunchclock Oct. 4 at 12:02 AM
$PSTV Possibility of reaching over $1.00 by October 19, 2025 Based on analyst ratings and the stock's recent price movements, Plus Therapeutics' stock price could potentially rise above $1.00 by October 19, 2025.
0 · Reply
Thess5
Thess5 Oct. 3 at 11:25 PM
$IMG Fully loaded here! .2722! 100% gainer they say Monday! $ICU In .60 out of.70 In .575 out of.61 $QCLS In $5.94 out $5.63 $BURU In .1419 out .17 In .154 out .16 $PSTV In .60 out .70 Recent wins one loss!✅✅✅✅🔍
3 · Reply
RedHottie
RedHottie Oct. 3 at 10:20 PM
$PSTV LFG!!
0 · Reply
bambus3001
bambus3001 Oct. 3 at 10:19 PM
$PSTV Buy out Ja es sieht so aus bei den Umsätzen seit Wochen Kursziel 5-6 💰💰💰💰💰
1 · Reply